drugset / Trial / NCT06762808
Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC
NaSingle-groupOpen-labelTreatment
Summary
A single-arm, phase II study for patients with detectable HPV CtDNA at 12 weeks or longer after completion of definitive therapy for non-metastatic, HPV+ squamous cell carcinoma.
Timeline
- Start
- 2025-05-01
- Primary completion
- 2025-08-08
- Completion
- 2025-08-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Talazoparib | Small molecule | — | Intravenous |